Covid-19 jabs that were developed by US drug makers Pfizer and Moderna may not be as effective against the 'Delta' variant compared to as they were against the original strain of the virus, says study
The Russian Direct Investment Fund (RDIF) has proposed that US drugmaker Pfizer start joint trials with Sputnik Light as a booster COVID-19 vaccine shot, the RDIF said on Wednesday."Delta cases surge in US & Israel shows mRNA vaccines need a heterogeneous booster to strengthen & prolong immune response. #SputnikV pioneered mix & match approach, combo trials & showed 83.1% efficacy vs Delta. Today RDIF offers Pfizer to start trial with Sputnik Light as booster," it said in a Tweet.It further said that Sputnik V is the first in the world to offer combo trial to AstraZeneca in November 2020, co-sponsored mix & match trials with AstraZeneca, Moderna and Sinopharm."Sputnik V was the 1st in the world to offer combo trial to AstraZeneca in Nov 2020, co-sponsored mix & match trials with AstraZeneca, Moderna & Sinopharm. Since then heterogeneous boosting pioneered by Sputnik proved to be effective vs mutations," it added further.According to an official ...
The percentage gain was the stock's biggest one-day rise since Nov. 9, when Pfizer released positive data for its Covid-19 vaccine
BioNTech and partner Pfizer have supplied more than one billion doses of their vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca the German biotech Group said
It is not clear whether J&J is seeking indemnity against adverse events following vaccination like its US peers
The terms of the deals were renegotiated after Phase 3 clinical trial data showed vaccines from the two companies are more effective than some rivals
Zydus Cadila DNA-plasmid vaccine is the prime contender. It has held trials on children aged 12 years and above
China says it has made alternative proposal for virus origin probe, EU pulls ahead of US in vaccinations, and other pandemic-related news across the globe
The New York drugmaker had previously projected vaccine sales for the year of $26 billion.
Business Standard brings you the top headlines on Wednesday
Total antibody levels start to wane six weeks after complete immunisation with Pfizer and AstraZeneca vaccines, and can reduce by more than 50 per cent over 10 weeks, according to The Lancet journal
The number of people who have recuperated from the disease has surged to 30,503,166, while the case fatality rate stands at 1.34 per cent
The federal government is buying 200 million more doses of the Pfizer coronavirus vaccine to prepare for future needs, such as boosters and shots for kids under 12
Bharti Pravin Pawar says Centre has set up team to deal with various issues related to procurement of Covid-19 vaccine from foreign firms
A team of central government officials is in continuous dialogue with foreign Covid vaccine manufactures like Pfizer, Moderna and Johnson and Johnson to discuss and address various issues
Ramaphosa has welcomed the announcement of a collaboration between the country's Biovac Institute and US pharma giant Pfizer as a breakthrough in the protection of African nations against COVID
A host of lesser-known vaccine makers are eyeing contract manufacturing opportunities for global and domestic majors
Pfizer says it plans to meet with top US health officials Monday to discuss the drugmaker's request for federal authorization of a third dose of its Covid-19 vaccine
The announcement by US drugmaker Pfizer of a plan on developing a booster dose of its Covid-19 vaccine has heightened hesitancy amongst unvaccinated population and sparked confusion across country
FDA and EU regulator say no need for extra dosage at this time